题    目：ALK as target for cancer immunotherapy 

报告人：Roberto Chiarle, MD, Associate Professor, Children's Hospital Boston, Harvard Medical School, USA 

主持人：王海芸 副教授

时    间：2016年9月13日星期二上午10:00-11:10

地  点：生命与医学院大楼1102报告厅

Biography: 

      Dr. Chiarle has focused his recent work on chromosomal translocations that involve the Anaplastic Lymphoma Kinase gene, which is involved in the pathogenesis of Anaplastic Large Cell Lymphoma (ALCL), Non-Small Cell Lung Cancer (NSCLC) and other tumors (Chiarle et al. Nat Medicine, 2005, Chiarle et al. Nat Rev Cancer, 2008). He developed a method to study the genome-wide distribution of chromosomal translocations in lymphoma (Chiarle et al., Cell 2011) and discovered recurrent FBXO11 mutations in diffuse large B cell lymphoma (Duan et al., Nature 2012). His group has developed mouse models for both ALK-rearranged lymphoma and lung carcinoma to study the molecular pathogenesis of ALK-rearranged tumors and to explore novel therapeutic options for ALK tumors. Recently, his group developed an ALK vaccine that instructs the immune system to recognize and eliminate ALK-rearranged lymphoma and lung cancer cells (Chiarle et al. Nat Medicine, 2008, Voena et al. Cancer Immunology Research 2015). Based on these results, a Phase I clinical trial will be conducted in ALK-positive NSCLC in 2017-2018 through the joined effort of the Boston Children’s Hospital, the Dana-Farber Cancer Institute and the Koch Institute at MIT, with Dr. Chiarle’s lab primarily involved in the trial. In this project, a combinatorial immunotherapeutic approach to treat ALK-driven cancers will be tested.